Loading...
Anti-FLT4 Recombinant Antibody Products
Loading...Anti-FLT4 Products
- Human Anti-FLT4 Recombinant Antibody (TAB-292CL) (TAB-292CL)
-
- Species Reactivity: Human
- Type: Human IgG1
- Application: ELISA
-
- Derivation: Human
- Species Reactivity: Human
- Type: ADCC enhanced antibody
- Recombinant Mouse Anti-Human FLT4 Antibody (MOB-2181MZ)
-
- Species Reactivity: Human
- Type: Mouse antibody
- Application: ELISA, WB
- Rat Anti-Flt4 Recombinant Antibody (clone AFL4) (NEUT-850CQ)
-
- Species Reactivity: Mouse
- Type: Rat IgG2a, κ
- Application: IHC, Block, ELISA, IP, WB
- Mouse Anti-Flt4 Recombinant Antibody (clone CBL842) (NEUT-851CQ)
-
- Species Reactivity: Mouse
- Type: Mouse IgG1
- Application: Neut
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: WB, ELISA
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG2a
- Application: WB, IHC, FC
- Mouse Anti-FLT4 Recombinant Antibody (VS3-CJ913) (VS3-CJ913)
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: IHC
- Mouse Anti-FLT4 Recombinant Antibody (clone 4H4) (VS3-XY715)
-
- Type: Mouse IgG1
- Application: ELISA, WB
-
- Species Reactivity: Mouse
- Type: Rabbit IgG
- Application: ELISA
-
- Species Reactivity: Mouse
- Type: Rabbit IgG
- Application: ELISA
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: ELISA
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: ELISA
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG2a, κ
- Application: WB, FC, IHC, IP
- Anti-Human FLT4 Recombinant Antibody (9D9F9) (TAB-015CQ)
-
- Species Reactivity: Human
- Application: ELISA, FC
- Anti-Human FLT4 Recombinant Antibody scFv Fragment (9D9F9) (TAB-015CQ-S(P))
-
- Species Reactivity: Human
- Application: ELISA, FC
- Anti-Human FLT4 Recombinant Antibody Fab Fragment (9D9F9) (TAB-015CQ-F(E))
-
- Species Reactivity: Human
- Application: ELISA, FC
-
- Species Reactivity: Mouse
- Type: Rabbit IgG
- Application: ELISA
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: ELISA
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG
- Application: WB, ELISA
- Human Anti-FLT4 scFv-Fc Chimera (VS-0425-FY54) (VS-0425-FY54)
-
- Species Reactivity: Human
- Type: Human IgG1, scFv-Fc
- Application: ELISA
-
- Species Reactivity: Human
- Target: FLT4
- Host Animal: Mouse
- Application: ELISA, FC, Cell-uptake
- Anti-FLT4 Immunohistochemistry Kit (VS-0525-XY2585)
-
- Species Reactivity: Human
- Target: FLT4
- Application: IHC
- Anti-Mouse FLT4 Immunohistochemistry Kit (VS-0525-XY2586)
-
- Species Reactivity: Mouse
- Target: FLT4
- Application: IHC
-
- Species Reactivity: Human
- Type: Human IgG1
- Application: ELISA
-
- Species Reactivity: Human
- Host Animal: Human
- Target: FLT4
- Application: ISZ, Cyt, FuncS
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
At Creative Biolabs, we are proud to offer a superior range of anti-FLT4 recombinant antibody products, meticulously engineered to meet the stringent demands of global research and therapeutic development. Our cutting-edge antibodies provide unparalleled specificity and performance, empowering scientists worldwide to accelerate their discoveries in critical biological pathways and disease mechanisms.
FLT4: A Promising Target for Cancer Therapy
Fms-like tyrosine kinase 4 (FLT4), also known as Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3), is a receptor tyrosine kinase primarily involved in lymphangiogenesis and vascular development. Its critical function in lymphatic vessel formation positions it as a key player in both normal physiology and various pathological conditions. Recent research consistently highlights FLT4's significant role in disease progression, particularly its contribution to cancer progression and metastasis by promoting tumor angiogenesis and facilitating lymphatic spread. Studies, such as those focusing on novel peptides targeting FLT4, increasingly demonstrate its therapeutic potential, especially in challenging malignancies like acute myeloid leukemia (AML). This underscores its importance as a compelling target for developing innovative treatments and diagnostic tools.
Alternative Names
Fms-related tyrosine kinase 4; FLT41; LMPH1A; PCL; VEGFR3; FLT-4; VEGFR-3; fms related tyrosine kinase 4; LMPHM1; fms related receptor tyrosine kinase 4; CHTD7.
Background
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.
Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, RAS pathway related proteins
Intracellular, Membrane, Secreted (different isoforms)
Group enriched (Hepatic stellate cells, Extravillous trophoblasts, Adipocytes, Endothelial cells)
Immune cell enriched (MAIT T-cell)
Cell line enhanced (AN3-CA, BEWO, HEK93, HL-60, HUVEC TERT2, JURKAT, T-47d, TIME)
Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-2. Identified in a complex with SRC and ITGB1.
Kinase, Receptor, Transferase, Tyrosine-protein kinase
Anti-FLT4 rAb Products
Our anti-FLT4 recombinant antibody products are meticulously designed with superior specificity and affinity, ensuring reliable and precise detection and modulation of FLT4. This high degree of specificity is crucial for minimizing off-target binding and ensuring accurate experimental results in diverse applications. Produced using advanced recombinant technology, these antibodies offer exceptional batch-to-batch consistency, which is vital for research reproducibility across multiple experiments and long-term studies, and significantly reduced immunogenicity, a key advantage for potential preclinical development and therapeutic applications. Their high purity and robust performance provide researchers with a truly dependable and versatile tool for their most critical experiments, from fundamental target validation to complex functional studies and drug screening.
| Cat. No. | Product Name | Target Species | Host Species | Applications |
| TAB-292CL | Human Anti-FLT4 Recombinant Antibody (TAB-292CL) | Human | Human IgG1 | ELISA |
| ZG-0353J | Mouse Anti-FLT4 Recombinant Antibody (ZG-0353J) | Human | Mouse IgG | WB, ELISA |
| VS3-QX433 | Mouse Anti-FLT4 Recombinant Antibody (clone 818CT12.1.1) | Human | Mouse IgG2a | WB, IHC, FC |
| VS3-XY715 | Mouse Anti-FLT4 Recombinant Antibody (clone 4H4) | Mouse IgG1 | ELISA, WB | |
| MOB-2181MZ | Recombinant Mouse Anti-Human FLT4 Antibody | Human | Mouse antibody | ELISA, WB |
Table 1. Featured anti-FLT4 recombinant antibody products at Creative Biolabs.
Creative Quality Control
Creative Biolabs implements a rigorous quality control process for all anti-FLT4 recombinant antibodies. Each product undergoes comprehensive validation, including ELISA, Western Blot, flow cytometry, and immunohistochemistry, to guarantee optimal performance, specificity, and sensitivity. This meticulous approach ensures that our antibodies consistently meet the highest industry standards, providing researchers with confidence in their experimental results.
Fig.1 SDS-PAGE analysis of anti-FLT4 antibody
(Cat# TAB-292CL, Creative Biolabs).
Fig.2 WB analysis of anti-FLT4 antibody
(Cat# ZG-0353J, Creative Biolabs).
Customer Reviews
Mouse Anti-FLT4 Recombinant Antibody (clone 818CT12.1.1) (VS3-QX433)
Human Anti-FLT4 Recombinant Antibody (TAB-292CL) (TAB-292CL)
Recombinant Rabbit Anti-FLT4 Detection Antibody (clone R12-4S-1) (VS3-WK1957)
rAb Production
Our anti-FLT4 recombinant antibodies are produced in state-of-the-art facilities utilizing proprietary expression systems, ensuring high yield and purity. We employ stringent purification protocols to minimize contaminants, delivering a product that is highly active and suitable for diverse research and therapeutic applications, from basic research to drug discovery.
Featured Anti-FLT4 Recombinant Antibody Production Platforms
Fig.3 Milligram-scale anti-FLT4 recombinant antibody production.
Fig.4 Gram-scale anti-FLT4 recombinant antibody production.
rAb Modalities
Creative Biolabs offers anti-FLT4 recombinant antibodies in multiple modalities, providing flexibility for various experimental designs and applications.
Fig.5 Full-length anti-FLT4 recombinant antibody production and modalities.
FLT4-Targeted Drug Information
| Organization | Research phase | Product Category | Condition |
| Akeso Biopharma (Originator) | Phase III |
Cancer Immunotherapy Human Monoclonal Antibodies |
Cancer, gastroesophageal junction (adenocarcinoma) Cancer, gastrointestinal Cancer, solid tumor |
|
AffaMed Therapeutics Allgenesis Biotherapeutics (Originator) |
Phase II |
Fc Fusion Proteins Polypeptides, from 41 AA |
Diabetic macular edema Fibrosis Inflammatory disorders Neovascularization, retinal Occlusion, retinal vein Wet macular degeneration (exudative) |
| Shanghai Henlius Biotech (Originator) | Phase I |
Cancer Immunotherapy Follow-on Products Human Monoclonal Antibodies |
Cancer Cancer, colorectal, metastatic Cancer, gastroesophageal junction (adenocarcinoma) Cancer, lung (non-small cell) (NSCLC) Cancer, stomach |
| LynkCell (Originator) | Phase I | Humanized Monoclonal Antibodies |
Cancer, cervix Cancer, colorectal Cancer, ovary Cancer, solid tumor Cancer, stomach |
|
MabSpace Biosciences (Transcenta) Transcenta (Originator) |
Phase I |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, solid tumor |
| Henlix Biotech (Originator) | Phase I |
Cancer Immunotherapy Human Monoclonal Antibodies |
Cancer, solid tumor |
| Beijing Dongfang Biotech (Originator) | Clinical |
Cancer Immunotherapy Human Monoclonal Antibodies |
Cancer, lung (non-small cell) (NSCLC) |
| University of Pennsylvania (Originator) | Preclinical |
CRISPR/Cas9 System Nucleases Lipid Nanoparticles Single Guide RNA (sgRNA) Single-stranded oligoribonucleotide (RNA) |
Cancer, lung |
| Universite de Lausanne (Originator) | Preclinical |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Melanoma |
| Zhengzhou University (Originator) | Preclinical |
Double-stranded oligoribonucleotide (RNA) Micelles Nanoparticles Small Interfering RNA (SiRNAs) |
Pre-eclampsia |
| Food and Drug Administration (Originator) | Preclinical |
Bispecific Antibody Fusions Cancer Immunotherapy Fusion Proteins Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) |
Triple negative breast cancer |
| University of Mississippi Medical Center (Originator) | Preclinical |
Carrier-Mediated Drug Delivery Fusion Proteins Polypeptides, from 41 AA Vascular Endothelial Growth Factors (VEGF) |
Hypertension, pregnancy-induced |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Table 2. Public drug targeting FLT4.
Creative Biolabs is committed to improving scientific research with our excellent anti-FLT4 recombinant antibody solutions. We encourage you to browse our wide portfolio and learn how our experience may help you achieve your next breakthrough. Please contact us if you want precise details, specialized solutions, or want to discuss your specific project requirements.


